Digital assessment of cognitive function in long COVID patients
Exploring Long-COVID Impact on Cognition Through Digital Neuropsychological Assessment
This study is testing a new way to check how well people with long COVID think and remember things to help better understand their symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | All |
| Sponsor | Luxembourg Institute of Health Government |
| Locations | 1 site (Luxembourg) |
| Trial ID | NCT06391970 on ClinicalTrials.gov |
What this trial studies
The Digital Cognition study, also known as DigiCog, aims to evaluate cognitive function in individuals who have experienced long-term symptoms following COVID-19 infection. This study builds on the existing Predi-COVID project, which has been tracking patients for over a year to understand the long-term health effects of COVID-19. By utilizing advanced technology from VIEWMIND, the study will screen for neurocognitive conditions and improve the diagnosis of long COVID through non-invasive cognitive assessments. Participants will undergo cognitive screening to assess various cognitive functions such as memory, attention, and decision-making.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 25 to 65 who have previously participated in the Predi-COVID study or have had COVID-19 at least once before 2022.
Not a fit: Patients with pre-existing psychological or neurological disorders, or those unable to use the digital assessment tools due to poor eyesight, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of cognitive impairments associated with long COVID.
How similar studies have performed: While there have been studies on cognitive effects of COVID-19, this specific approach utilizing VIEWMIND's technology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who have previously participated in the Predi-COVID study (Registration number NCT04380987), or who have experienced COVID-19 at least once before 2022. * Participants who have signed the informed consent form * Participants aged between 25 and 65 years old Exclusion Criteria: * Psychological or neurological disorders history especially those detected before the COVID-19 disease (e.g. epilepsy, stroke, chronic fatigue) as well as treatment that could interfere with the assessment (e.g., antipsychotics, antidepressants, mood stabilizers, antiepileptics, benzodiazepines) * Poor eyesight, rendering the use of the digital device impossible * Inability to speak the proposed languages
Where this trial is running
Luxembourg
- Luxembourg Institute of Health, LCTR — Luxembourg, Luxembourg (Recruiting)
Study contacts
- Principal investigator: Magali PERQUIN, PhD — Luxembourg Institute of Health
- Study coordinator: Magali PERQUIN, PhD
- Email: magali.perquin@lih.lu
- Phone: (+352) 26970
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.